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A B S T R A C T
Nonylphenol (NP) is an industrial chemical with estrogenic activity both in vivo and in vitro; estrogens
play a critical role in the development of prostate and may be the cause of some pathological states,
including cancer. In this study we examined the effects of NP on human prostate non tumorigenic
epithelial cells (PNT1A) investigating on cell proliferation, interaction with estrogen receptors (ERs) and
gene expression of genes involved in prostate diseases. We found that NP affects cell proliferation at
106M, promoting a cytoplasm-nucleus translocation of ERa and not ERb, like the natural estrogen 17b-
estradiol (E2). Moreover, we showed that NP enhances gene expression of key regulators of cell cycle.
Estrogen selective antagonist ICI182780 in part reverted the observed effects of NP. These results conﬁrm
the estrogenic activity of NP and suggest that other transduction pathways may be involved in NP action
on prostate.
ã 2016 Elsevier Ireland Ltd. All rights reserved.
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Nonylphenol (NP) is generated by the degradation of non-
ylphenol ethoxilates (NPEs). NPEs are chemicals widely used as
non ionic surfactants in the manufacture of rubber and plastic for
domestic, industrial and agricultural products (Fiege et al., 2000;
Langford, 2002; Vazquez-Duhalt et al., 2005). Due to its high
hydrophobicity and low solubility NP accumulates in several
environmental matrices, such as seas, rivers, soils, groundwaters
and sediments, in a range between 1013 to 106M (Berryman
et al., 2004; Careghini et al., 2015; Vazquez-Duhalt et al., 2005). It
was also found as a contaminant of food and drinking water
(Gyllenhammar et al., 2012; Maggioni et al., 2013; Soares et al.,
2008). Human exposure to NP may occur by inhalation, cutaneous
absorption and ingestion of contaminated food or water (Guenther
et al., 2002; Soto et al.,1991). In this regard, NP was found in human
amniotic ﬂuid, urine and plasma samples, breast milk, fetal cord
serum, placenta and maternal blood, with levels in these tissues
generally varying from 1010 to 109M (Calafat et al., 2005; Huang
et al., 2014). Hovewer, in some cases, concentrations of NP have* Corresponding author at: Department of Biology, University of Naples,
“Federico II” Via Mezzocannone 8, Naples, 80134, Italy.
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0300-483X/ã 2016 Elsevier Ireland Ltd. All rights reserved.been reported to be much higher in human samples. In this regards
in breast milk of healthy Italian women, Ademollo et al. (Ademollo
et al., 2008) detected about 107M of NP as well as in urine and in
plasma of textile and housekeeping workers were found the same
NP levels (Chen et al., 2005). Instead, in maternal cord blood, Chen
et al. (Chen et al., 2008) found a concentration of NP of about
106M.
NP belongs to the subclass of endocrine disrupting chemicals
(EDCs) that mimic the endogenous estrogens, called xenoestro-
gens (Falconer et al., 2006; Wozniak et al., 2005), that also
includes dioxins, polychlorinated biphenyls, hexachlorocyclohex-
ane, octylphenol and bisphenol A (Kuo et al., 2012; Forte et al.,
2016). Estrogenic activity of NP has been reported both in vitro (de
Weert et al., 2008; Soto et al., 1991; White et al., 1994) and in vivo,
in reproductive and in non reproductive tissues, such as brain
(Blom et al., 1998; Laws et al., 2000; Nagel et al., 1999; ter Veld
et al., 2008; Xia et al., 2008; De Falco et al., 2014, 2015) and it has
been shown that NP interacts with estrogen receptors (ERs),
competing with the natural estrogen 17b-estradiol (E2) (Bechi
et al., 2006; Kwack et al., 2002; White et al., 1994), although with
less speciﬁcity (Bechi et al., 2010; Blom et al., 1998; Nagel et al.,
1999).
Estrogens predominantly bind two nuclear receptors: the
estrogen receptor alpha (ERa) and the estrogen receptor beta
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with similar afﬁnities (Siewit et al., 2010). ERs mediated estrogen
signaling in reproductive tissues but also in non-reproductive
tissues as the brain, lungs, colon, prostate and cardiovascular
system (Shanle and Xu, 2011). In the cell, E2 is able to activate both
genomic and non-genomic responses. In the genomic pathway, E2
mediates target gene regulation through binding directly DNA at
estrogen response elements (EREs) or indirectly through tran-
scription factors like Sp1 or AP-1 (Kushner et al., 2000; Saville et al.,
2000); the non-genomic pathway is not mediated by ERa or ERb
but through the G-protein coupled receptor, GPR30, that localizes
in the plasma membrane activating rapid responses such as
increased levels of c-AMP (Filardo et al., 2007; Lin et al., 2009;
Wang et al., 2010).
Several studies have suggested the role of estrogens in normal
and aberrant growth of prostate, alone or in synergy with
androgens (Ho et al., 2011) and epidemiological and experimental
studies underline a relationship between estrogens/xenoestrogens
and pathogenesis of prostate cancer (PCa) (Bostwick et al., 2004;
Ho et al., 2006). Neonatal treatment with Bisphenol A (BPA), a well-
known xenoestrogen, was reported to induce high-grade prostatic
intraepithelial neoplasia in Sprague-Dawley rats (Ho et al., 2006)
and to increase cell proliferation of urogenital sinus epithelium
(UGE) in the primary prostatic ducts of CD1 mice (Timms et al.,
2005). BPA was also found to increase the number of basal
epithelial cells in the adult prostate of BALB/c mice (Ogura et al.,
2007). Recently, Tarapore et al. (2014) found in prostate cancer
patients high BPA urinary levels compared to non prostate cancer
patients.
Despite the relationship between estrogen and prostate, the
precise functions of the two ER subtypes in this gland remain
unclear; several authors have reported differential expression
patterns of the two receptors between the epithelial and stromal
compartment of the prostate, with ERa localized predominantly
in the stroma and ERb in the epithelium (Fixemer et al., 2003;
Leav et al., 2001; Tsurusaki et al., 2003; Weihua and Warner,
2002).
Considered this background and given the human exposure to
EDCs, the estrogen-like action of NP is conceivable to inﬂuence the
normal growth of prostate and to be the cause of some pathological
states of this gland, affecting the male reproductive functions.
Thus, in this study we evaluated the effects of NP on the
proliferation of human non tumorigenic prostate cells (PNT1A),
which is responsive to sex hormones (Stephen et al., 2004), the
cellular localization of ERa and ERb after exposure to NP and gene
expression of genes involved in pathological states of the prostate
such as cyclin D, Ki67, p53 and IL1-b. We performed the same
experiments treating cells with the natural estrogen E2 and with
the selective antagonist of estrogen receptors ICI 182,780 (Osborne
et al., 2004). This study aims to facilitate the understanding of the
mechanisms by which xenoestrogens and estrogens may exert
their activity on prostate.
2. Material and methods
2.1. Cell culture
PNT1A cells (a human prostate cell line established by
immortalization of adult prostate epithelial cells) were obtained
from the European Collection of Cell Culture (ECACC Salisbury, UK).
PNT1A cells were grown in red phenol free RPMI-1640 medium
(LONZA, Basel, Switzerland), supplemented with 10% dextran-
coated charcoal fetal bovine serum (FBS) (GIBCO, Grand Island,
NY), 2 mM L-glutamine and antibiotics (100 U/mL penicillin/
streptomycin, 10 mg/mL gentamicin) in a humidiﬁed incubator at
37 C and 5% CO2. When conﬂuent, the cells were detachedenzymatically with trypsin-ethylenediamine tetra-acetic acid and
subcultured into a new cell culture ﬂasks. The medium was
replaced every 2 days. Cells were used for experiments between
passages 5–20.
2.2. Chemicals
Nonylphenol (NP), 17b-Estradiol (E2) and selective estrogen
antagonist ICI 182,780 (ICI) were purchased from Sigma-Aldrich
(Sigma Aldrich, St. Louis, MO) and were dissolved in DMSO
(Invitrogen Carlsbad, CA). NP, E2 and ICI were diluted with culture
medium at ﬁnal concentrations from 1012 to 106M for NP and E2
and 105M for ICI. In all the experiments with the inhibitor, ICI was
added 1 h prior to start treatments. Final concentration of DMSO in
the medium did not exceed 0.01%.
2.3. MTT assay
The effects of NP or E2 on PNT1A cells proliferation was
evaluated using the 3-[4,5-dimethylthiazol-2-yl]-3,5 diphenyl
tetrazolium bromide (MTT) test (Sigma Aldrich, St. Louis, MO).
Cells were seeded in 200 mL of growth medium (5 104 cells/
well) in 96-well plates and hormone deprived (1% FBS) for 24 h.
Then, NP or E2 was added after dilution to an appropriate
concentration (from 1012M to 106M), with or without 105M
ICI. Control cells were treated with vehicle (DMSO 0.01%). The test
was performed for 24 h of incubation. After the incubation period,
10 mL of a MTT solution was added to each well. After 4 h of 37 C
incubation, the culture medium was gently aspirated and
replaced by 100 mL of DMSO/isopropanol (1:1) in order to
dissolve the formazan crystals. The absorbance of the solubilized
dye, which correlates with the number of living cells, was
measured with a microplate reader at 570 nm. The test was
performed in triplicate.
2.4. Fluorescence microscopy
PNT1A cells were seeded in 4-well chamber slide (Sarstedt,
Nürnbrecht, Germany) overnight at a density of 5 104/well. After
24 h serum starvation (1% FBS), cells were incubated with 106M
NP or 106M E2, with or without 105M ICI for four different
times: 15 min, 1 h, 2 h and 6 h. Control group was treated only
with vehicle (DMSO 0.01%). Control and treated cells were ﬁxed
with methanol for 10 min at RT, permeabilized with 0.25% Triton
X-100 for 10 min, washed in PBS, and blocked in 5% normal goat
serum (NGS) for 1 h at RT. Then cells were subjected to
immunoﬂuorescence protocol using a mouse monoclonal anti-
human ERa (Santa Cruz Biotechnology, Santa Cruz, CA, Cat. sc-
8005) and a mouse monoclonal anti- human ERb antibodies
(Santa Cruz, Cat. sc-373853), diluted 1:100 in 1% NGS for 24 h at
4 C. For detection of ERa and ERb, secondary goat anti-mouse
Alex Fluor 488 (Cat. A11001, Invitrogen, Carlsbad, CA), dilution
1:200 in 1% NGS was used. Cell nuclei were counterstained with
0.1 mg/mL Höechst (Invitrogen, Carlsbad, CA, Cat. H3570).
Negative control for ERa and ERb was performed by avoiding
incubation with the primary antibodies (Supplementary data
Fig. S1). Fluorescent images were taken on an Axioskop (Carl
Zeiss, Milano, Italy) epiﬂuorescence microscope using a 40
objective. Axiocam MRc5 and the acquisition software Axiovision
4.7 (Carl Zeiss) were used to capture the images in different
channels (Alexa Fluor 488, Höechst 33258). Three independent
immunoﬂuorescence experiments were performed for each
experimental conditions and different ﬁelds were randomly
chosen for data analysis. Then, images were processed with the
Image J software (developed by Wayne Rasband, National
Institutes of Health, USA).
Table 1
Primers used in qPCR.
Gene 50-Forward-30 50-Reverse-30
Cyclin D CGTGGCCTCTAAGATGAAGGA CGGTGTAGATGCACAGCTTCTC
Cyclin E GATGACCGGGTTTACCCAAA CCTCTGGATGGTGCAATAATCC
Ki67 CCCGTGGGAGACGTGGTA TTCCCGTGACGCTTCCA
p53 TCTGTCCCTTCCCAGAAAACC CAAGAAGCCCAGACGGAAAC
IL1-b ACGATGCACCTGTACGATCACT CACCAAGCTTTTTTGCTGTGAGT
GAPDH CAAGGCTGTGGGCAAGGT GGAAGGCCATGCCAGTGA
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Nuclear and cytoplasmatic proteins were extracted from
PNT1A cells after two and six hours of treatment with 106M
NP, 106M E2, with or without 105M ICI. Control cells were
treated with 0.01% of DMSO and western blot was performed for
detection of ERa and ERb. Different buffers were prepared to
isolate cytoplasmic/membrane and nuclear proteins: harvest
buffer (10 mM HEPES pH 7.9, 50 mM NaCl, 0.5 M sucurose, 0.1 mM
EDTA, 0.5% Triton X-100 and freshly added 1 mM DTT, 10 mM
tetrasodium pyrophosphate, 100 mM NaF, 1 mM PMSF, 4 mg/mL
Aprotinin and 2 mg/mL Pepstatin A), buffer A (10 mM HEPES pH
7–9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA and freshly added
1 mM DTT, 1 mM PMSF, 4 mg/mL Aprotinin and 2 mg/mL Pepstatin
A) and buffer B (10 mM HEPES pH 7.9, 500 mM NaCl, 0.1 mM EDTA,
0.1 mM EGTA 0.1% NP-40 and freshly added 1 mM DTT, 1 mM
PMSF, 4 mg/mL Aprotinin and 2 mg/mL Pepstatin A). 10 cm cell
dishes with conﬂuent PNT1A cells were placed on ice for 10 min
and washed twice with ice cold PBS. Then 100 mL of PBS-EDTA
1 mM was added and cells were scraped and transferred to a
microcetrifuge tube. The collected cells were then centrifuged at
3000 rpm for 5 min at 4 C and then resuspended in cold harvest
buffer, incubated on ice for 5 min and subsequently centrifuged at
1000 rpm for 10 min to pellet nuclei. Then the supernatant was
transferred into a new tube and centrifuged at 14000 rpm for
15 min, in order to clear the supernatant. This latter contains the
cytoplasmic and membrane proteins. Nuclear pellet was then
resuspended in buffer A, centrifuged at 1000 rpm, the superna-
tant was discarded. Then 4 vol of buffer B were added and the
tubes were vortex for 15 min at 4 C to loosen pellet. Finally, a
centrifugation for 10 min at 14,000 rpm at 4 C was performed and
the supernatant that contain nuclear extract was transferred into
a new tube. Protein concentration was determined with Bradford
assay (Biorad).
2.6. Western blot
50 mg of protein extracts for each sample was separated by 10%
SDS-PAGE and transferred onto a nitrocellulose membrane.
Membranes were blocked with 5% milk in TBS-Tween for 2 h at
room temperature and then incubated with primary antibodies in
TBS-Tween and 5% milk overnight. Blocked membranes were then
incubated with anti-ERa (1:500) or anti-ERb (1:500) and with
mouse anti-human b-tubulin (1:2000) (Santa Cruz, Cat. sc-5274)
or mouse anti-human HDAC2 (1:2000) (Santa Cruz, Cat. sc-55542)
overnight and then detected using appropriate horseradish
peroxidase-coupled secondary antibody (Santa Cru, Cat. sc-
2005) and visualized with enhanced chemiluminescence (Amer-
sham, Thermo Fisher Scientiﬁc, Milano, Italy). The purity of nuclear
and cytoplasmic fractions was conﬁrmed using anti-HDAC-2 and
anti-b-tubulin, respectively. All antibodies have been used to
probe the same experimental membrane. In detail, before
incubation with another primary antibody, the membranes have
been stripped with the stripping solution: 100 mM 2-Mercaptoe-
thanol, 1% SDS, 62.5 mM Tris-HCl pH 6.7 and incubated at 50 C for
30 min with agitation and, subsequently, the membrane have been
re-equilibrated in TBS and then blocked with 5% milk in TBS-Tween
for 2 h at room temperature. The rendering of stripping has been
tested by evaluating the ECL- signal after treatment with the
stripping solution. Only when the signal of the previous antibody
was absent, the membrane was incubated with a new antibody.
Immunoblotting data were analyzed using ImageJ software to
determine optical density (OD) of the bands. The OD reading was
normalized on anti-b-tubulin and anti-HDAC2 to account for
variations in loading. For each time of treatment (i.e. 2 h, 6 h, 2 hwith ICI) were analyzed data of three independent western
blotting.
2.7. RNA extraction and RT-qPCR
mRNA expression levels of estrogen target genes were analyzed
using real-time PCR. Total RNA from PNT1A control cells and
treated for 24 h with 106M E2 or 106M NP, with or without
105M ICI was extracted using Trizol (Life Technologies, Carlsbad,
CA). After puriﬁcation from genomic DNA with TURBO DNA-freeTM
Kit (Ambion, Life Technologies), the total amount of RNA was
quantiﬁed with a NanoDrop spectrophotometer. cDNAs were
synthesized from 1 mg RNA using the High Capacity cDNA Reverse
Transcriptase (Life Technologies) and quantitative PCR (RT- qPCR)
was performed by using the 7500 Real-Time PCR System and
SYBR1 Select Master Mix 2X assay (Applied Biosystem, Foster City,
CA, USA). All primers used (Table 1) were designed according to the
sequences published on GenBank using Primer Express software
version 3.0 and primer efﬁciencies were tested prior to perform
qPCR. The amount of target cDNA was calculated by comparative
threshold (Ct) method and expressed by means of the 2DDCt
method (Livak and Schmittgen, 2001) using the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as housekeeping gene, which
expression was not affected by the treatment. Three separate
experiments (n = 3) were performed for RT-qPCR and each sample
was tested in triplicate.
2.8. Statistical analysis
Data reported in graphs are expressed as mean values SEM for
the indicated number of independent determinations. The
statistical signiﬁcance was calculated by the one way ANOVA
with Bonferroni’s multiple comparison test, and differences were
considered statistically signiﬁcant when the P value was at least
<0.05.
3. Results
3.1. Cell proliferation assay
To determine if NP affects cellular proliferation, PNT1A cells
were treated with increasing concentration of NP (from 1012M to
106M) for 24 h of exposure; to assess any similarities, treatment
was performed also exposing cells with E2; the same experiments
were also carried out in presence of 105M ICI. NP stimulated
PNT1A cells proliferation at the highest concentration we used
(106M) (Fig. 1a). At lower concentrations, we did not observe any
signiﬁcant effects when compared to control group. 105M ICI
inhibited the proliferation induced by 106M NP. Similarly,
treatment with E2 stimulated PNT1A cells proliferation from
109M to 106M, with the greatest effect showed at 106M
(Fig. 1b). E2 induced proliferation is strongly inhibited by adding
ICI. Fig. 1c shows as E2 has a greater effect compared to NP on
PNT1A cells proliferation.
Fig. 1. MTT assay after 24 h of exposure to nonylphenol (NP) and 17b- estradiol (E2) alone or in combination with ICI 182, 780 (+I). NP stimulates PNT1A cells proliferation at
106M (a) while E2 at 109M, 108M, 107M and 106M (b). 105M ICI (I) reverts this effect. E2 shows the greatest effect on proliferation if compared to nonylphenol (c). In
graph is reported the absorbance measured at 570 nm which correlates with the number of living cells. a, response signiﬁcantly different than the vehicle control (P < 0.05); a’,
response signiﬁcantly different than the vehicle control (P < 0.01); b, response signiﬁcantly different than cells without ICI (P < 0.05).
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3.2.1. Localization of ERa
We investigated on estrogen receptors ERa localization after
106M NP and 106M E2 treatment, in order to evaluate the
interaction between NP and ERs. After 15 min and 1 h ERa
remained localized in the cytoplasm after both NP and E2
treatments (data not shown). After 2 h of treatment, NP did not
affect ERa cellular localization, that was localized in the cytoplasm,
as in control. On the contrary, in E2 treated cells for 2 h, ERa
localized predominantly in the nucleus (Fig. 2).
After 6 h of exposure, both in PNT1A cells treated with NP and
E2, ERa shifted from the cytoplasm to the nucleus that appeared to
be strongly positive, with a weak cytoplasmic ﬂuorescence if
compared to control (Fig. 2).
In PNT1A cells pre-treated with ICI ERa was found in the
cytoplasm both after 2 and 6 h of treatment with nuclei completely
negatives (Fig. 3).
3.2.2. Localization of ERb
ERb localization after treatment with 106M NP and 106M E2
was also investigated; data after 15 min and 1 h (data not shown) as
well as after 2 h and 6 h of exposure did not reveal any differences
between control and exposed cells. ERb was localized in the
cytoplasm of PNT1A cells and cell nuclei appeared with a weak
signal (Fig. 4).
3.3. Western blot analysis
After separation of cytoplasmic and nuclear proteins we
performed a translocation study of ERa and ERb with a western
blot analysis, in order to conﬁrm microscopy results after 106M
NP and E2 exposure. Densitometric analyses were normalized for
cytoplasmic and nuclear extracts with b-tubulin (55 Kda) and
HDAC2 (55 KDa), respectively. After 2 h of exposure (Fig. 5) we
found ERa protein (molecular weight 66 KDa) in the cytoplasm of
NP treated and non treated PNT1A cells whereas optical density
values were signiﬁcantly lower in E2 treated cells (Fig. 5a,b).
Moreover, after 2 h nuclear proteins revealed a signal only in E2
treated cells (Fig. 5a). ERb (56 KDa) after 2 h of treatment was
found only in cytoplasmic fractions (Fig. 5a,c). No signal for HDAC2
and b-tubulin in the cytoplasm and nucleus proteins, respectively,
suggest that protein separation was performed correctly.
After 6 h of exposure (Fig. 6) we observed a nuclear transloca-
tion of ERa both in NP and E2 treated cells (Fig. 6a,b). However,
densitometry did not reveal signiﬁcant differences in nuclear
extracts between NP and E2 treated cells (Fig. 6b). In contrast,
values were signiﬁcantly lower in the cytoplasm in treated cells
compared to control (Fig. 6b). ERb was found only in cytoplasmaticfractions (Fig. 6a,c) and there were not signiﬁcant differences in
optic density between treated and non treated cells (Fig. 6c).
Western blot for ERa localization performed in presence of
105M ICI after two (Fig. 7a,b) and 6 h of treatment (Fig. 7c,d)
revealed ERa exclusively in cytoplasm proteins, with a weak signal
in the nuclear extracts after 6 h of exposure (Fig. 7c). No
statistically signiﬁcant differences were showed comparing non
treated and treated cells (Fig. 7b,d).
3.4. RT- qPCR analysis
In order to investigate if NP is able to affect gene expression, RT-
qPCR analysis of genes involved in cell cycle regulation and in
pathological states of prostate were investigated after 24 h of
exposure. NP enhanced mRNA levels of Cyclin D (Fig. 8a), Cyclin E
(Fig. 8b), Ki67 (Fig. 8c) and IL1-b (Fig. 8e) while it did not affect p53
expression (Fig. 8d). Interestingly, ICI reduced gene expression of
Cyclin D (Fig. 8a) and Ki67 (Fig. 8c) in PNT1A cells treated with NP,
while it did not inhibit gene expression of Cyclin E (Fig. 8b) or IL1-b
(Fig. 8e). E2 signiﬁcantly affected gene expression up-regulating
Cyclin D (Fig. 8a) and Ki67 (Fig. 8c). This induction was strongly
inhibited by ICI (Fig. 8a,c).
4. Discussion
EDCs are receiving more and more attention by scientiﬁc
community, due to their ability to mimic endogenous hormones
and altering the metabolism of organisms (De Falco et al., 2014). NP
belongs to the family of xenoestrogens and its estrogenic activity is
well documented both with in vitro (de Weert et al., 2008; Soto
et al.,1991; White et al.,1994) and in vivo studies (Laws et al., 2000;
ter Veld et al., 2008). In this work we seek to investigate the effects
of NP on human prostate cells PNT1A, precisely evaluating its
estrogenic action in terms of proliferation, interaction with ERs and
gene analysis of genes involved in cell cycle regulation and
aberrant physiology of prostate. Few studies investigated the
effects of NP on prostate, both on cellular and animal models. These
ﬁndings did not characterize any molecular mechanisms and
results often appear to be in conﬂict. For example, Lee et al. showed
that NP is able to reduce the weight of the prostate in rats, in a dose
dependent manner (Lee, 1998). In the same study, authors
demonstrated that ICI reverted this effect. Similarly, Who et al.
obtained the same result but with higher concentration of NP (Woo
et al., 2007). Moreover, gestational exposure to NP was reported to
affect prostate morphology in F1 rats (Jie et al., 2010). In contrast,
other authors failed to demonstrate any adverse effects on rat
prostate caused by NP (Inaguma et al., 2004; Odum and Ashby,
2000). These contrasting data may be explained by the time and
the way of NP dosage, as well as by the duration of treatment. We
conducted our experiments also testing the effects of E2 and ICI.
Fig. 2. Localization of ERa after 2 and 6 h of exposure to NP and E2. E2 promotes translocation of ERa to the nucleus at both time of treatment, while NP at 6 h. PNT1A cells
were plated in chamber slide under hormone deprived conditions. 24 h later, cells were treated with 106M NP or 106M E2. ERa (Alexa Fluor 488) and nuclear staining
(Höechst) were analyzed by immunoﬂuorescence. Scale bar 10 mm.
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Fig. 3. Localization of ERa after 2 and 6 h of exposure to NP and E2 combined with ICI (+I). ICI inhibits ERa nucleus translocation at both time considered. Cells were pre-
treated for 1 h with 105M ICI and then treated with 106M NP or 106M E2. ERa (Alexa Fluor 488) and nuclear staining (Höechst) were analyzed by immunoﬂuorescence.
Scale bar 10 mm.
26 M. Forte et al. / Toxicology 357–358 (2016) 21–32We showed that NP stimulated PNT1A cells proliferation after 24 h
of exposure at 106M as well as E2 did. However, E2 affected
PNT1A cells proliferation also at lower concentrations. Interest-
ingly, ICI reverted NP and E2 proliferative stimuli. These results
suggest that NP may interfere with normal cell cycle of PNT1A cells
as reported by other authors in different cell lines (Choi et al., 2011;
Manente et al., 2011). Recently, Gan et al. (Gan et al., 2015) in
human prostate epithelial cell line RPWE-1 showed a reduction in
cell viability after 24 h exposure to NP. The incongruity between
our results and those of Gan et al. can be explained by the different
concentrations used. In this study, no effects were reported at 106NP and the decrease in cell proliferation appeared to be evident
only at high concentration (105–104M).
With two different approaches, we studied the localization of
ERa and ERb in a time course analysis testing the concentrations
(106M) that showed the greatest effect on cell proliferation. We
demonstrated that E2 induced cytoplasm-nucleus translocation of
ERa at both time tested, while NP only after six hour of exposure.
Surprisingly, both E2 and NP did not affect ERb localization. ICI
inhibited the ERa translocation observed with NP and E2 alone.
Both proliferation and localization data conﬁrm the estrogenic
activity of NP. However, the greatest biological responses showed
Fig. 4. Localization of ERb after 2 and 6 h of exposure to NP and E2. In all the images ERb is localized in cellular cytoplasm. PNT1A cells were plated in chamber slide under
hormone deprived conditions. 24 h later, cells were treated with 106M NP or 106M E2. ERb (Alexa Fluor 488) and nuclear staining (Höechst) were analyzed by
immunoﬂuorescence. Scale bar 10 mm.
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Fig. 5. Western blot analysis and nuclear and cytoplasmic quantiﬁcation of ERa and ERb after 2 h of exposure to 106M NP and E2. E2 induces nucleus translocation of ERa
while ERb was found only in the cytoplasmatic proteins (a). The graphs represented the Optical density (OD) ratio of ERa and ERb normalized to the OD of Tubulin b for
cytoplasmatic proteins and to the OD of HDAC2 for nuclear proteins (b). (N = 3 separate experiments) a, response signiﬁcantly different than the cytoplasmatic control
(P < 0.05); b’, response signiﬁcantly different than the nuclear control (P < 0.01)
28 M. Forte et al. / Toxicology 357–358 (2016) 21–32by E2 can be explained by its best binding afﬁnity with ERs
compared to NP (Laws, 2000). Notwithstanding the lowest
responses to NP, we can speculate that its proliferative effects,
as for E2, is mediated by the interaction with ERa. On this issue, it
is well known the role of ERa in cellular proliferation process and
carcinogenesis of prostate, while some authors suggested that
ERb seems to be involved in apoptosis of prostate cells (Hartman
et al., 2012). For example, it has been reported in knockout ERb
mice prostatic hyperplasia and cancer (Weihua et al., 2001).
Moreover, in mice and rats prostate, like in human, it has been
shown that ligands that interact with ERb may reduce prolifera-
tion (Ellem and Risbridger, 2009; Omoto et al., 2005; Prins and
Korach, 2008).
To assess if the presence of ERa in the nucleus led to the
activation of transcription, we analyzed gene expression of E2 gene
targets also known to be deregulated in pathological state of the
prostate. We demonstrated that NP was able to upregulate Cyclin D,
Cyclin E, Ki67 and IL1-b gene expression whereas E2 induced
upregulation only of Cyclin D and Ki-67. Moreover, we showed that
up-regulation of Cyclin D and Ki67 is mediated by estrogen
signaling pathways, while the induction of Cyclin E and IL1-b
involved an estrogen independent pathways, since ICI did not
revert this induction. These results of gene expression are in
agreement with the showed induced proliferation caused by NP
and E2. In this regard, it is well known that Cyclin D and Cyclin E
promoting G1/S phase transition of cell cycle (Kastan and Bartek,
2004) and are often used to screening the carcinogenic potential of
EDCs (Diamanti-Kandarakis et al., 2009). Moreover, it has been
reported that overexpression of Cyclin D, Ki67, Cyclin E and IL1b are
a prognostic factors prostate cancer (Aaltomaa et al., 2006; Deyet al., 2013; Sfanos and De Marzo, 2012). In particular, down-
regulation of Cyclin D and Cyclin E has been shown to inhibit tumor
progression in different prostate cell lines (Alagbala et al., 2006;
Chinni et al., 2001; Lin et al., 2015). In addition, the null effect
showed for p53, the hallmark of apoptosis, reinforce the idea that
NP has a role in promoting prostate cells survival (Gan et al., 2011;
Gumulec et al., 2014).
This data, together with the less estrogenic activity of NP in
terms of proliferation and interaction with ERa strongly suggest
that NP may activate also other transduction pathways, such as the
G-protein coupled estrogen receptor GPR30 (Filardo et al., 2007) or
the androgen receptor (ARs) (Wang et al., 2010). In this regard, in a
recent study, Kim et al. showed that NP induced human
tumorigenic prostate cells (LNCaP) proliferation in a pathway
mediated by ARs (Kim et al., 2016). In addition to ARs mediate
pathways, in epithelial non tumorigenic cells DU145, Gan et al.
(Gan et al., 2014) provided evidences about the involvement of
GPR30 in NP induced proliferation, when used at concentration
from 108 to 106M. Interestingly, according with our data and
despite the different prostate model used, in both studies, the
concentration that showed the best effects was 106M in both the
studies.
Considering the exposure level of NP, 106M represents an high
dose of NP, found rarely in human samples, such as in breast milk
and in umbilical cord blood (Chen et al., 2005). Furthermore, it is
far from the tolerable daily intake limit values for NP (Woo et al.,
2007). Despite these considerations, it should not be under-
estimated the adverse effects that NP may exert when combined
with circulating estrogens or with other EDCs which we are
simultaneously exposed. This phenomena, commonly known as
Fig. 6. Western blot analysis and nuclear and cytoplasmic quantiﬁcation of ERa and ERb after 6 h of exposure to 106M NP and E2. ERa was found in nuclear proteins after E2
and NP treatment while ERb was found only in the cytoplasmatic proteins (a). The graphs represented the Optical density (OD) ratio of ERa and ERb normalized to the OD of
Tubulin b for cytoplasmic proteins and to the OD of HDAC2 for nuclear proteins (b). (N = 3 separate experiments) a, response signiﬁcantly different than the cytoplasmatic
control (P < 0.05); b’, response signiﬁcantly different than the nuclear control (P < 0.01).
Fig. 7. Western blot analysis and nuclear and cytoplasmic quantiﬁcation of ERa after pre-treatment with 105M ICI 182,780 (+I). ICI inhibits cytoplasm-nucleus translocation
of ERa after 2 h of exposure to 106M E2 (a–b) and after 6 h of exposure to 106M E2 and NP (c–d). The graphs represented the Optical density (OD) ratio of ERa normalized to
the OD of Tubulin b for cytoplasmic proteins and to the OD of HDAC2 for nuclear proteins (b, d). (N = 3 separate experiments) no signiﬁcantly differences.
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Fig. 8. RT-qPCR analysis after 24 h of exposure to 106M NP and E2, alone or in combination with 105M ICI (+I). Cyclin D (a), Cyclin E (b), Ki67 (c), p53 (d) and IL1b (e) relative
mRNA levels were normalized using GAPDH as housekeeping gene. (N = 3 separate experiments) a, response signiﬁcantly different than the vehicle control (P< 0.05); a’,
response signiﬁcantly different than the vehicle control (P < 0.01); a”, response signiﬁcantly different than the vehicle control (P < 0.001) b, response signiﬁcantly different
than cells without ICI (P < 0.05); b’, response signiﬁcantly different than cells without ICI (P < 0.01).
30 M. Forte et al. / Toxicology 357–358 (2016) 21–32“cocktail effect” is a feature widely accepted for EDCs risk
management (Bergman et al., 2012).
In conclusion, we demonstrated that NP acts on PNT1A cells
with similar effects if compared to E2, probably mediated by ERa
and it may be involved in a deregulation of cell cycle, leading to
aberrant proliferation of prostate epithelial cells, which in turn
may contribute to pathological states, including cancer. We are
also providing data on the dual role of ERs in prostate cells.
Notwithstanding the ﬁndings of this study, further evidences
remain to be investigated in order to best characterize the risk of
NP exposure for prostate diseases. In addition, more cellular and in
vivo models will be needed. However, our data may help
epidemiologists to consider and monitoring the association
between NP and prostate pathologies.
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